



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 401/12	A1	(11) International Publication Number: WO 91/18895 (43) International Publication Date: 12 December 1991 (12.12.91)
(21) International Application Number: PCT/SE91/00402 (22) International Filing Date: 5 June 1991 (05.06.91) (30) Priority data: 9002043-9 7 June 1990 (07.06.90) SE (71) Applicant: AKTIEBOLAGET ASTRA [SE/SE]; S-151 85 Södertälje (SE). (72) Inventor: BRÄNDSTRÖM, Arne, Elof ; Anders Mattssonsgatan 13 B, S-415 06 Göteborg (SE). (74) Agents: DANIELSSON, Sten et al.; AB Astra, Patent Department, S-151 85 Södertälje (SE).		(81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: IMPROVED METHOD FOR SYNTHESIS (57) Abstract The present invention relates to an improved method for the synthesis of omeprazole, comprising the steps of reacting 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-1H-benzimidazole with m-chloroperoxy-benzoic acid in a methylene chloride solution at a substantially constant pH of about 8.0 to 8.6; extracting the reaction mixture with aqueous NaOH; separating the aqueous phase from the organic phase; and adding an alkyl formate to the aqueous phase, resulting in crystallization of omeprazole.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Improved method for synthesis

Technical field

- 5 The present invention relates to an improved method for the synthesis of 5-methoxy-2-[[[4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl-1H-benzimidazole, referred to under its generic name omeprazole throughout the following specification and claims.

10

Prior art

- US-A-4 255 431 discloses a process for the synthesis of omeprazole comprising the steps of reacting 5-methoxy-2-
15 [(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-1H-benzimidazole in a methylene chloride solution with m-chloroperoxybenzoic acid resulting in the formation of omeprazole and m-chlorobenzoic acid. omeprazole is highly sensitive to acids, and the reaction mixture has to be
20 maintained at a low temperature to prevent excessive decomposition in the reaction mixture.

- The product is worked-up by filtering-off of m-chlorobenzoic acid formed during the reaction. The filtrate is
25 diluted with methylene chloride, is extracted with Na_2CO_3 solution, dried and evaporated. The resulting omeprazole product is contaminated with starting materials and by-products.

30 Summary of the invention

The object of the present invention is to provide an improved method for the synthesis of omeprazole, which eliminates the drawbacks of previously known methods.

35

This object is achieved according to the present inven-

tion, which is characterized by the steps of reacting 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-1H-benzimidazole (below denoted Compound I) with m-chloroperoxybenzoic acid in a methylene chloride solution at a substantially constant pH of about 8.0 to 8.6; extracting the reaction with aqueous NaOH; separating the aqueous phase from the organic phase; and adding an alkyl formate to the aqueous phase, resulting in crystallization of omeprazole.

10

The m-chloroperoxybenzoic acid is suitably used in an amount of 0.7 - 1.4 molar equivalents of Compound I, and preferably in an amount of 0.9 - 1.2 molar equivalents.

15 According to one embodiment of the invention, the alkyl formate is methylformate or ethylformate, methylformate being preferred.

The alkyl formate is suitably used in an amount of 1.2 - 2.0 molar equivalents of Compound I, and preferably in an amount of 1.5 - 1.8 molar equivalents.

One important feature of the method according to the invention is that unreacted sulfide is not transferred into the aqueous phase upon the extraction with aqueous NaOH. Another important feature is that m-chlorobenzoic acid does not crystallize upon the addition of methylformate to the aqueous phase, thereby eliminating the need of filtering-off of m-chlorobenzoic acid in a previous step.

The pH of the reaction mixture may be maintained within the pH range of 8.0 - 8.6 with the aid of pH static titration with NaOH or with the use of a buffer. Preferred buffers are sodium bicarbonate and potassium bicarbonate.

A great advantage of the method according to the invention is that the reaction takes place in the organic methylene chloride phase while the m-chlorobenzoic acid formed during the reaction goes into the aqueous phase containing
5 the buffer, in the case a buffer is used. Because of this, omeprazole formed does not stay in contact with the acid and the reaction may be performed at a temperature above 0°C.

10 According to one embodiment of the invention the pH of the aqueous NaOH phase is kept at above about 12.

According to another embodiment of the invention the crystallization of omeprazole is performed at a pH of
15 above 9.

The invention will be further illustrated below with a non-limiting example.

20 Example

5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-1H-benzimidazole (16.2 g; 0.0492 mol) is reacted with m-chloroperoxybenzoic acid (13.6 g; 0.0537
25 mol) in CH_2Cl_2 acting as a solvent at a pH of 8.6, which is maintained by the presence of KHCO_3 (5.6 g; 0.056 mol) acting as a buffer. The temperature is maintained at about 0°C during the addition.

30 Diluted NaOH is added to a pH above 12 and the CH_2Cl_2 phase is separated off.

Methylformate (4.7 g) is charged to the water phase and the pH is kept above 9, whereupon omeprazole crystallizes.
35 The crystals are filtered off and are washed with water and methanol at a temperature of about 0°C. The washed crystals are dried under vacuum. Yield: 15.6 g (92 %).

C l a i m s

1. An improved method for the synthesis of omeprazole, characterized by the steps of reacting 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-1H-benzimidazole (Compound I) with m-chloroperoxybenzoic acid in a methylene chloride solution at a substantially constant pH of about 8.0 to 8.6; extracting the reaction mixture with aqueous NaOH; separating the aqueous phase from the organic phase; and adding an alkyl formate to the aqueous phase, resulting in the crystallization of omeprazole.
2. Method according to claim 1, characterized in that the m-chloroperoxybenzoic acid is used in an amount of 0.7 - 1.4, preferably 0.9 - 1.2, molar equivalents of Compound I.
3. Method according to claim 1 or 2, characterized in that the alkyl formate is methylformate.
4. Method according to claims 1 - 3, characterized in that pH of the reaction mixture is maintained within the pH range of 8.0 - 8.6 with the aid of pH static titration with NaOH.
5. Method according to claims 1 - 4, characterized in that pH of the reaction mixture is maintained within the pH range of 8.0 - 8.6 with the use of a buffer.
6. Method according to claim 5, characterized in that the buffer is sodium bicarbonate or potassium bicarbonate.
7. Method according to claims 1 - 6, characterized in that the pH of the aqueous NaOH phase is

kept at above about 12.

8. Method according to claims 1 - 7, c h a r a c t e -
r i z e d in that the alkyl formate is added in an amount
5 of 1.2 - 2.0, preferably 1.5 - 1.8, molar equivalents of
Compound I.

9. Method according to claims 1 - 8, c h a r a c t e -
r i z e d in that the crystallization of omeprazole is
10 performed at a pH of above 9.

INTERNATIONAL SEARCH REPORT

International Application No PCT/SE 91/00402

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC5: C 07 D 401/12		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
IPC5	C 07 D	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in Fields Searched ⁸		
SE,DK,FI,NO classes as above		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	US, A, 4255431 (AKTIEBOLAGET HÄSSLE) 10 March 1981, see example 1 --	1
A	US, A, 4182766 (HOFFMANN-LA-ROCHE INC) 8 January 1980, see example 17 --	1
A	WO, A1, 8705021 (AKTIEBOLAGET HÄSSLE) 27 August 1987, see example 1 --	1
A	EP, A, 0197013 (AKTIEBOLAGET HÄSSLE) 8 October 1986, see example 2 --	1
<p>* Special categories of cited documents:¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
28th August 1991	1991 -09- 1 0	
International Searching Authority	Signature of Authorized Officer	
SWEDISH PATENT OFFICE	Göran Karlsson	

International Application No. PCT/SE 91/00402

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
A	EP, A, 0163842 (F. HOFFMANN-LA ROCHE & CO.) 11 December 1985, see example 4 -- -----	1

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 91/00402

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 91-06-27.
The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A- 4255431	81-03-10	AT-B- 374471	84-04-25
		AT-B- 374472	84-04-25
		AT-B- 374473	84-04-25
		AT-B- 375365	84-07-25
		AT-B- 389995	90-02-26
		AU-B- 529654	83-06-16
		AU-D- 4602779	79-10-18
		CA-A- 1127158	82-07-06
		CA-A- 1129417	82-08-10
		EP-A-B- 0005129	79-10-31
		JP-C- 1312930	86-04-28
		JP-C- 1504537	89-07-13
		JP-A- 54141783	79-11-05
		JP-A- 58192880	83-11-10
		JP-B- 60034956	85-08-12
		JP-B- 63053191	88-10-21
		SE-A- 7804231	79-10-15
		US-A- 4337257	82-06-29
		US-A- 4508905	85-04-02
US-A- 4182766	80-01-08	AT-B- 368152	82-09-27
		AU-B- 519711	81-12-17
		AU-D- 3981778	80-03-20
		CA-A- 1106849	81-08-11
		DE-A- 2840591	79-03-29
		EP-A-B- 0001279	79-04-04
		FR-A-B- 2403340	79-04-13
		GB-A-B- 2004281	79-03-28
		JP-A- 54059274	79-05-12
		NL-A- 7809529	79-03-21
		OA-A- 6054	81-06-30
		SE-A- 7809792	79-03-20
		US-A- 4248880	81-02-03
WO-A1- 8705021	87-08-27	EP-A- 0242341	87-10-21
		JP-T- 63502658	88-10-06
EP-A- 0197013	86-10-08	JP-A- 61205211	86-09-11
EP-A- 0163842	85-12-11	AU-B- 589555	89-10-19
		AU-D- 4122885	85-10-24
		AU-D- 4136685	85-10-24
		JP-A- 60233070	85-11-19
		SU-A- 1362402	87-12-23

ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. PCT/SE 91/00402

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the Swedish Patent Office EDP file on 91-06-27. The Swedish Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0163842	85-12-11	SU-A- 1396965	88-05-15
		US-A- 4634710	87-01-06
		US-A- 4981861	91-01-01